PerpEquities

Equity · Healthcare

Abbott Laboratories (ABT) perpetual futures

ABT perpetual futures on 2 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade ABTUSDT.

Abbott Laboratories is a global healthcare company developing and selling pharmaceuticals, diagnostics, nutritional products, and medical devices.

$116.16+5.6%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · BingX (ABTUS-USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

2/2 live markets
Venues
2
Live markets
2/2
24h volume
$351.4K
Open interest
$104.1K
Best liquidity
$14.9K
MEXC
Tightest spread
+21.5 bps
MEXC
Highest volume
$238K
BingX
Settlement mix
USDT · 2/2
Perp/spot vol.
0.00x
Spot volume $1.5B
OI / float
0.00%
Float $199.8B
Spot performance
1D+5.59%
5D+8.82%
1M+15.39%
6M+32.51%
YTD-7.81%
1Y-7.25%

Venue matrix

2 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeABTUS-USDTTrading$116.17+45.1% APR
+0.041% every 8h		+100.7 bps$1.4K$238K$1.1KUSDT-
MEXCTradeABT/USDTTrading$116.16+7.4% APR
+0.00680% every 8h		+21.5 bps$14.9K$113.3K$103KUSDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Thin liquidity · 1 of 2 venues absorb $10k · Typical cost: +88.6 bps

Cheapest execution: MEXC · +88.6 bps

No fresh book data: BingX

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

ABT
MEXC · ABT/USDT$14.9K

Tightest spread

ABT
MEXC · ABT/USDT+21.5 bps

Highest volume

ABT
BingX · ABTUS-USDT$238K

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-04 · next report 2027-01-28 · Updated 3h ago
All financials →

Valuation & key figures

Market cap
$199.9B
Updated 3h ago
Revenue
$48.2B
Trailing 12 months
Revenue growth
+13%
Next fiscal year
Profit margin
+9.7%
P/E
42.8
Peer P/E 36.1
P/S
4.1
Peer P/E
36.1
Similar listed perps
Free cash flow
$9.1B
Trailing 12 months
Net income
$4.7B
Trailing 12 months
Revenue estimate
$50B
Next fiscal year
Earnings
2027-01-28
Revenue est. $13.2B · Updated 3h ago
Dividend
$0.63
2026-10-15
Revenue (TTM)$48.2B+10.0% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)15.2%-2.5 pp vs a year agoOperating income $7.35B
Net income (TTM)$4.7B-66.4% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$9.06B+31.0% vs a year agoCapex -$207M
Diluted EPS (TTM)$2.70-66.2% vs a year agoSum of the last 4 quarters
Net cash-$26.9B-415.8% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-21): revenue in line, EPS in lineRevenue $13B vs $13B expected (+0.2%); EPS $1.42 vs $1.42 (0.0%).
  • Revenue growth accelerating: 14.5% year on yearQ3 '26 revenue $13B, against an average of 8.0% over the four quarters before.
  • Operating margin 15.2% (TTM), -2.5 pp on a year agoOperating income grew -5.6% while revenue grew 10.0%.
  • 12.0% of pre-tax profit is eaten by non-operating lossesPre-tax income $6.56B vs operating income $7.35B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Revenue by business line

latest quarter
LineRevenuey/yShare
Diagnostic Products$3.09B-47.6%24.6%
Medical Devices$5.85B+9.0%46.5%
Nutritional Products$2.14B-3.1%17.0%
Established Pharmaceutical Products$1.5B+8.4%11.9%
Established Pharmaceuticals–––
Other$5M–0.0%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 232 lines Abbott Laboratories reported to the SEC

Next catalyst

Catalysts

Earnings
2027-01-28
Revenue est. $13.2B · Updated 3h ago
Dividend
$0.63
2026-10-15

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20265.52$50B+13%17
FY 20275.93$53.7B+21%18
FY 20286.50$57.1B+29%14
FY 20297.21$61.4B+39%7
FY 20307.94$65.8B+48%11
Q1 20271.23$12.6B+13%11

Company events

6
2027-01-28EarningsActual - / Estimate 1.64-
2026-10-21Earnings · Before market openActual 1.42 / Estimate 1.42In line
2026-10-15Dividend$0.63-
2026-07-16EarningsActual 1.31 / Estimate 1.28Beat
2026-07-15Dividend$0.63-
2026-04-16EarningsActual 1.15 / Estimate 1.14Beat

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
NVO$186B3.810.8+33.9%16GILD$216.4B7.0-56.3-12.5%10PFE$175.5B2.843.6+6.3%13DHR$162B6.337.7+16.9%4ISRG$159.8B13.854.0+25.5%10AMGN$258.7B6.627.5+24.1%15VRTX$139.2B10.735.1+30.6%4TMO$261.6B5.537.2+15.0%4

Company data

Company intelligence

Updated: Nov 5, 2026, 10:18 AM UTC

Company profile

Sector
Healthcare
Industry
Medical - Devices
Chief executive
Robert Ford
Employees
115,000
IPO date
Mar 17, 1980
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei2.78
Piotroski scorei6/9
Overall ratingiC
Owner earningsi$3.08B$1.77 per share
ESG risk ratingiBIndustry rank: 11 out of 170

Rating factors

Return on equityi
1
Return on assetsi
1
Debt to equityi
1
Price to earningsi
2
Price to booki
1

Company press releases

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of strokePRNewsWireAbbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy SystemPRNewsWireAbbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve diseasePRNewsWireAbbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatmentPRNewsWireAbbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancerPRNewsWireAbbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS GuidancePRNewsWire

Congressional disclosures

Senate

House

Market cap history
$200.77B+9.0%Aug 26 – Nov 26
$174.47B$188.92B$203.36BHigh: $203.36B · 2026-08-24Low: $174.47B · 2026-10-05Latest: $200.77B · 2026-11-04Aug 26Sep 26Oct 26Nov 26
Latest: $200.77B · 2026-11-04High: $203.36B · 2026-08-24Low: $174.47B · 2026-10-05
Largest fund holders
FundWeightShares held
VTI0.23%54.9M
VOO0.26%45.4M
SCHD3.74%42.5M
IVV0.28%23.1M
1657.T0.22%23.1M
XSP.TO0.27%23M
XWD.TO0.2%23M
SPY0.27%21.1M
FXAIX0.26%20.9M
VTV0.65%16.5M
XLV2.71%12.7M
VIG0.76%9.8M

Analyst track record

How the analysts covering ABT have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings154440
Analysts3538
Buy / hold / sell145 / 9 / 0407 / 33 / 0
Upgrades / downgrades / initiations2 / 2 / 23 / 3 / 7
Price targets hit / missed3 / 134 (2%)3 / 402 (1%)
Avg. return after a rating (TipRanks)-17.8%-21.2%
Best / worst call+17.5% / -38.1%+17.5% / -38.1%

After buy calls on this stock: median 21-day move +1.0% vs S&P 500 -1.2% (n = 409)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Shagun Singh ChadhaRBC Capital75% hit rate on this stock · 16 targets measuredBuytarget $125Oct 21, 2026
  2. Lee HambrightBernstein75% hit rate on this stock · 8 targets measuredBuytarget $125Jan 23, 2026
  3. Larry BiegelsenWells Fargo74% hit rate on this stock · 54 targets measuredBuytarget $120Oct 22, 2026

Latest ratings

DateAnalystCallTarget
Nov 2, 2026Adam MaederPiper SandlerBuyMaintained$118article ↗
Oct 30, 2026Travis SteedBank of America SecuritiesBuyReiterated$115article ↗
Oct 30, 2026Travis SteedBank of America SecuritiesBuyReiterated$115
Oct 27, 2026David ToungArgus ResearchHoldDowngraded–article ↗
Oct 26, 2026David ToungArgus ResearchHoldDowngraded–article ↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$90.00$100$110$120$130$140$150Dec 25 · Buy 20 · Hold 3 · Sell 0Dec 25Jan 26 · Buy 20 · Hold 3 · Sell 0Feb 26 · Buy 20 · Hold 3 · Sell 0Feb 26Mar 26 · Buy 19 · Hold 3 · Sell 0Apr 26 · Buy 19 · Hold 4 · Sell 0Apr 26May 26 · Buy 18 · Hold 4 · Sell 0Jun 26 · Buy 20 · Hold 4 · Sell 0Jun 26Jul 26 · Buy 22 · Hold 4 · Sell 0Aug 26 · Buy 23 · Hold 3 · Sell 0Aug 26Sep 26 · Buy 23 · Hold 2 · Sell 0Oct 26 · Buy 26 · Hold 2 · Sell 0Oct 26Nov 26 · Buy 26 · Hold 2 · Sell 0Dec 25 · avg. target $146Jan 26 · avg. target $140Feb 26 · avg. target $139Mar 26 · avg. target $138Apr 26 · avg. target $122May 26 · avg. target $120Jun 26 · avg. target $118Jul 26 · avg. target $120Aug 26 · avg. target $122Sep 26 · avg. target $122Oct 26 · avg. target $122Nov 26 · avg. target $122Dec 25 · month-end close $125Jan 26 · month-end close $109Feb 26 · month-end close $116Mar 26 · month-end close $103Apr 26 · month-end close $90.79May 26 · month-end close $85.60Jun 26 · month-end close $90.74Jul 26 · month-end close $106Aug 26 · month-end close $110Sep 26 · month-end close $98.83Oct 26 · month-end close $106Nov 26 · month-end close $106

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 2, 2026 · 154 ratings

Frequently asked questions

Where can I trade ABT perpetual futures?

Abbott Laboratories (ABT) perpetual futures trade on 2 crypto venues, including BingX, MEXC. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade ABT around the clock?

Yes. Unlike the underlying stock, ABT perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on ABT perpetuals?

Right now the ABT perp funding rate is +26.3% annualized (venue median), ranging from +7.4% to +45.1% across 2 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the ABT perp price compare to the Abbott Laboratories stock?

The venue-median ABT perp mark is $116.2 versus a reference stock price of $116.2, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a ABT perpetual future?

A ABT perpetual is a derivative that tracks the price of Abbott Laboratories with no expiry date. It lets you take long or short exposure to Abbott Laboratories on crypto venues, around the clock.

What is ABTUSDT perpetual?

ABTUSDT is the symbol most crypto exchanges use for the Abbott Laboratories perpetual settled in USDT (Tether). It tracks the ABT share price through an index, trades 24/7 with leverage and never expires.

Other Healthcare perps

Also listed on BingX

Also listed on MEXC

Embed this asset

ABT perpetuals · perpequities.comABT perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/abt-perp"><img src="https://perpequities.com/badge/abt-perp.svg" width="240" height="64" alt="ABT perpetuals · perpequities.com" loading="lazy"></a>

Raw data: JSON · CSV · API

Next step

Stay on top of ABT perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for ABT — one email every Sunday.

Watchlist and alerts

Price and funding alerts for ABT, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X